Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Castle Biosciences (Nasdaq:CSTL) announced that chief financial officer Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal.

Rhea-AI Summary

Castle Biosciences (Nasdaq:CSTL) announced that chief financial officer Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal. He is one of 22 CFOs recognized in Greater Houston for financial leadership and organizational impact.

Stokes has served as CFO since December 2017, helping guide Castle Biosciences’ 2019 Nasdaq IPO and supporting growth through multiple strategic acquisitions. Honorees will be celebrated July 30 and featured in the July 31 print and digital issues.

Argus Jun 23 session

+0.85% close to close Open Argus

Details

News Market Reaction – CSTL

On Jun 23, the day this news came out, CSTL closed 0.85% above the previous close.

Data tracked by StockTitan Argus for the Jun 23 session.

Market Context

This announcement highlights external recognition of Castle’s CFO, who guided the 2019 IPO and acqui...

Analysis

This announcement highlights external recognition of Castle’s CFO, who guided the 2019 IPO and acquisitions. Recent history shows shares often lag positive news; investors may watch future financial updates rather than awards for catalysts.

Key Figures

CFO honorees: 22 leaders Awards event date: July 30 Publication feature date: July 31 +4 more

CFO honorees

22 leaders

Number of chief financial officers recognized in Greater Houston area

Awards event date

July 30

Date honorees will be celebrated at awards event

Publication feature date

July 31

Houston Business Journal print and digital editions featuring honorees

CFO tenure start

December 2017

Month and year Frank Stokes became Castle’s chief financial officer

IPO year

2019

Year Castle Biosciences completed its Nasdaq initial public offering

Top 25 CFO honors

2 times

Number of times Stokes named a Top 25 CFO of Houston

Most recent Top 25 recognition

2024

Most recent year Stokes was named a Top 25 CFO of Houston

Historical Context

5 past events · Latest: Jun 16

5 events

1. Jun 16

   Product adoption milestone

   24h Move

   -1.0%

   TissueCypher test surpassing 100,000 clinical orders milestone announcement.

2. May 13

   Conference participation

   24h Move

   -2.6%

   Jefferies Global Healthcare Conference presentation and webcast details.

3. May 12

   Industry award win

   24h Move

   -2.1%

   AdvanceAD-Tx test receiving MedTech Breakthrough Genomics Innovation Award.

4. May 06

   Earnings and guidance

   24h Move

   -22.3%

   Q1 2026 results with raised full-year revenue guidance and growth metrics.

5. May 05

   Advocacy initiatives

   24h Move

   -3.6%

   Support for nationwide advocacy and screening during Skin Cancer Awareness Month.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

initial public offering

1 terms

initial public offering financial

"helping lead the company through its successful Nasdaq initial public offering in 2019"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Stokes was one of 22 financial leaders recognized in the Greater Houston area

FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been named a 2026 CFO Awards honoree by the Houston Business Journal.

Stokes is among 22 chief financial officers from across the Greater Houston area recognized for their financial leadership and contributions to their organizations' success. Honorees will be celebrated at an awards event on July 30 and featured in the July 31 print and digital editions of the Houston Business Journal.

"Frank exemplifies the combination of financial discipline and strategic vision that has allowed Castle Biosciences to grow and serve patients," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Frank has served as Castle's chief financial officer since December 2017, helping lead the company through its successful Nasdaq initial public offering in 2019 and supporting its growth through multiple strategic acquisitions."

"It is an honor to be recognized among so many outstanding financial leaders in Houston," Stokes said. "I am proud to work alongside a talented team at Castle as we advance our mission of improving patient care through innovative testing solutions, and I am grateful for this recognition."

Stokes has twice been named a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing), most recently in 2024.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-chief-financial-officer-frank-stokes-named-a-2026-cfo-awards-honoree-by-the-houston-business-journal-302807013.html

SOURCE Castle Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What recognition did Castle Biosciences (CSTL) CFO Frank Stokes receive in June 2026?

Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal. According to Castle Biosciences, he is one of 22 Greater Houston CFOs recognized for financial leadership and contributions to their organizations’ success, highlighting his role in the company’s growth.

How long has Frank Stokes served as CFO of Castle Biosciences (CSTL)?

Frank Stokes has served as Castle Biosciences’ chief financial officer since December 2017. According to Castle Biosciences, during his tenure he helped lead the company through its successful Nasdaq IPO in 2019 and supported growth through multiple strategic acquisitions and operational leadership.

When will the Houston Business Journal honor Castle Biosciences (CSTL) CFO Frank Stokes?

Frank Stokes and other honorees will be celebrated at an awards event on July 30, 2026. According to Castle Biosciences, the Houston Business Journal will also feature the honorees in its July 31 print and digital editions for broader recognition.

How has CFO Frank Stokes contributed to Castle Biosciences (CSTL) since joining?

Frank Stokes helped guide Castle Biosciences’ 2019 Nasdaq initial public offering and growth. According to Castle Biosciences, he has supported expansion through multiple strategic acquisitions, combining financial discipline and strategic vision to help the company improve patient care through innovative diagnostic testing solutions.

What other awards has Castle Biosciences (CSTL) CFO Frank Stokes received before 2026?

Frank Stokes has twice been named a Top 25 CFO of Houston by TOP CFOs. According to Castle Biosciences, his most recent recognition from that organization came in 2024, underscoring ongoing acknowledgment of his financial leadership in the Houston business community.